Bayer, one of the world’s largest pharmaceuticals, is poised to start locally producing its cardiovascular drug in Sanofi Turkey’s Lüleburgaz Facilities.
Within the framework of the project, Bayer is projecting to invest over EUR 4.5 million and to triple its value-based production volume. Planned to be commenced at the end of 2020, the project is the largest local investment project that Bayer has ever ventured beyond the German borders.
This localization project will enable Bayer to expand its stake of product localization in the cardiovascular market to 40 percent.
Releasing a comment on the proposed investment, Bayer Group President in Turkey/Iran Ingrid Drechsel said, “We are excited for our new localization project to be started in Turkey within this December. We took the decision to produce our cardiovascular drug in Turkey by cooperating with Turkey’s Ministry of Health. Bayer will continue investing in Turkey as it has been doing in the past 66 years.”